ReviewInternational journal of molecular sciences2022
Role of Nano-miRNAs in Diagnostics and Therapeutics.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Age-Related Cognitive Decline, Focus on Microbiome: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Fluorescent bionanosensor for picomolar detection of biomarkers in fluids.European biophysics journal : EBJ · 2026Article
- A near-infrared-controlled and logic gate sensing platform for the sensitive and specific detection of dual miRNAs.RSC advances · 2026Article
- Bioinformatics analysis to explore the potential prognostic utility of hsa-miR-103a-3p in head and neck squamous cell carcinoma.Scientific reports · 2025Article
- Genomic exploration of Bemisia tabaci microRNAs using predictive modeling and confirmation through experimental evidence.Scientific reports · 2025Article
- Associations between plasma and urinary heavy metal concentrations and the risk of prostate cancer.Scientific reports · 2025Article
- Plasma Humanin and Non-Coding RNAs as Biomarkers of Endothelial Dysfunction in Rheumatoid Arthritis: A Pilot Study.Non-coding RNA · 2025Article
- Role of non-coding RNA through nanomedicine: the novel therapeutic and diagnostic approaches.BioImpacts : BI · 2025Review
- Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.Medicina (Kaunas, Lithuania) · 2023Review
- Decoding the Microbiome's Influence on Rheumatoid Arthritis.Microorganisms · 2023Review
- The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors.International journal of biological sciences · 2023Review
- MicroRNAs, Stem Cells in Bipolar Disorder, and Lithium Therapeutic Approach.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNA) are key regulators of gene expression, controlling different biological processes such as cellular development, differentiation, proliferation, metabolism, and apoptosis. The relationships between miRNA expression and the onset and progression of different diseases, such as tumours, cardiovascular and rheumatic diseases, and neurological disorders, are well known. A nanotechnology-based approach could match miRNA delivery and detection to move beyond the proof-of-concept stage. Different kinds of nanotechnologies can have a major impact on the diagnosis and treatment of miRNA-related diseases such as cancer. Developing novel methodologies aimed at clinical practice represents a big challenge for the early diagnosis of specific diseases. Within this context, nanotechnology represents a wide emerging area at the forefront of research over the last two decades, whose potential has yet to be fully attained. Nanomedicine, derived from nanotechnology, can exploit the unique properties of nanometer-sized particles for diagnostic and therapeutic purposes. Through nanomedicine, specific treatment to counteract only cancer-cell proliferation will be improved, while leaving healthy cells intact. In this review, we dissect the properties of different nanocarriers and their roles in the early detection and treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.